Objective:

To identify distinct MASLD subgroups and examine differences in their metabolic, genetic, and clinical risk profiles.

Approach:

• Data: Researchers combined genomic information and electronic health records from two Mayo Clinic research cohorts.
• Analysis: Statistical analysis identified patient subgroups, which were then assessed in an independent cohort.

Key Findings:

• The analysis identified five subgroups with distinct metabolic, genetic, and disease-risk profiles; the patterns were reproduced in an independent cohort.
• Two subgroups had substantial metabolic disease and high rates of type 2 diabetes and sleep apnea. One was predominantly male and had elevated cardiovascular and kidney-related risks; the other was predominantly female and associated with obesity, mood disorde…
• A subgroup with relatively few metabolic complications had the highest overall liver-transplantation rate. Variants in TM6SF2, MBOAT7, and HSD17B13 were implicated in its elevated risk.
• A genetically influenced subgroup characterized by MASH had increased risks of advanced liver fibrosis and acute kidney failure.

Interpretation:

The authors report that conventional metabolic risk indicators alone may not identify all patients at greatest risk of severe liver disease. They describe integrating genomic risk profiles with routine clinical information as a potential way to refine classification and identify patients for closer monitoring.

Limitations:

• The findings are based on observational data.
• The proposed subtypes require further validation before they can inform routine clinical decisions.

Conclusion:

The researchers conclude that understanding distinct biological mechanisms in MASLD could help refine risk prediction, guide surveillance strategies, and support development of tailored treatments.

Sources:

• Article context; study published in Nature Communications